Dutkiewicz R, Albert D M, Levin L A
Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison 53792, USA.
Exp Eye Res. 2000 May;70(5):563-9. doi: 10.1006/exer.1999.0819.
The intraocular pressure-lowering drug latanoprost, a phenyl-substituted analogue of prostaglandin F2 alpha (PGF2 alpha), increases iris pigmentation in a small number of patients. In theory, this could be due to increased melanogenesis or melanocyte proliferation. To distinguish these two possibilities, the present study examined the effects of latanoprost on tyrosinase activity (the rate-limiting step for melanin synthesis) and mitotic index of cultured melanoma lines. Murine cutaneous melanoma lines (S91 and B16), and human uveal (OCM1, OCM3, and OM431) and cutaneous (SK-MEL5 and M21) melanoma lines were cultured with PGE1, PGE2, PGF2 alpha, latanoprost, or the adenylate cyclase stimulating agent forskolin. After treatment, tyrosinase was assayed with respect to its dopa oxidase activity using a colorimetric assay. PGE1, PGE2, PGF2 alpha, and latanoprost greatly increased tyrosinase activity in murine melanoma lines and caused small increases in tyrosinase activity in human uveal and cutaneous melanoma lines. Similar results were obtained with the cAMP-elevating compound forskolin. Cyclic AMP content, as determined by an enzyme-linked immunoassay, was similarly increased by all treatments, with forskolin being the most potent stimulator. Since the species difference in tyrosinase activity was observed without an apparent difference in induction of cAMP, latanoprost would appear to induce tyrosinase activity through a non-cAMP-dependent pathway. Finally, latanoprost and PGF2 alpha did not enhance the mitotic index of human uveal or cutaneous melanoma lines, measured by [6-3H] thymidine uptake, although they increased the mitotic index of one murine cutaneous line. Given that latanoprost induced tyrosinase activity, but did not increase the mitotic index in any of the human melanoma lines studied, this suggests that the in vivo iris pigmentation side effect of latanoprost may not result from increased cell division, but from elevated tyrosinase activity.
降眼压药物拉坦前列素是前列腺素F2α(PGF2α)的苯基取代类似物,在少数患者中会增加虹膜色素沉着。从理论上讲,这可能是由于黑素生成增加或黑素细胞增殖所致。为了区分这两种可能性,本研究检测了拉坦前列素对培养的黑色素瘤细胞系酪氨酸酶活性(黑色素合成的限速步骤)和有丝分裂指数的影响。将小鼠皮肤黑色素瘤细胞系(S91和B16)、人葡萄膜(OCM1、OCM3和OM431)及皮肤(SK-MEL5和M21)黑色素瘤细胞系分别与前列腺素E1(PGE1)、前列腺素E2(PGE2)、PGF2α、拉坦前列素或腺苷酸环化酶刺激剂福斯高林一起培养。处理后,采用比色法测定酪氨酸酶的多巴氧化酶活性。PGE1、PGE2、PGF2α和拉坦前列素可显著提高小鼠黑色素瘤细胞系中的酪氨酸酶活性,并使人类葡萄膜和皮肤黑色素瘤细胞系中的酪氨酸酶活性略有增加。使用福斯高林这种能提高环磷酸腺苷(cAMP)水平的化合物也得到了类似结果。通过酶联免疫测定法测定的cAMP含量在所有处理中均有类似增加,其中福斯高林是最有效的刺激剂。由于在cAMP诱导方面没有明显差异的情况下观察到了酪氨酸酶活性的物种差异,拉坦前列素似乎是通过非cAMP依赖途径诱导酪氨酸酶活性的。最后,尽管拉坦前列素和PGF2α增加了一个小鼠皮肤细胞系的有丝分裂指数,但通过[6-3H]胸苷摄取测定发现,它们并未提高人类葡萄膜或皮肤黑色素瘤细胞系的有丝分裂指数。鉴于拉坦前列素可诱导酪氨酸酶活性,但在所研究的任何人类黑色素瘤细胞系中均未增加有丝分裂指数,这表明拉坦前列素在体内引起的虹膜色素沉着副作用可能不是由细胞分裂增加所致,而是由酪氨酸酶活性升高引起的。